| Literature DB >> 12617750 |
Alvin Berger1, David M Mutch, J Bruce German, Matthew A Roberts.
Abstract
BACKGROUND: The functions, actions, and regulation of tissue metabolism affected by the consumption of long chain polyunsaturated fatty acids (LC-PUFA) from fish oil and other sources remain poorly understood; particularly how LC-PUFAs affect transcription of genes involved in regulating metabolism. In the present work, mice were fed diets containing fish oil rich in eicosapentaenoic acid and docosahexaenoic acid, fungal oil rich in arachidonic acid, or the combination of both. Liver and hippocampus tissue were then analyzed through a combined gene expression- and lipid- profiling strategy in order to annotate the molecular functions and targets of dietary LC-PUFA.Entities:
Year: 2002 PMID: 12617750 PMCID: PMC139963 DOI: 10.1186/1476-511x-1-2
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
N6/N3 LC-PUFA ratios [(20:4n6 + 22:4n6)/(20:5n3+22:5n3+22:6n3)] in whole brain, hippocampus, and hepatic phospholipid pools. Typically, the above ratios were highest following feeding of the AA-enriched diet, lowest following feeding of the FISH diet, and intermediary following feeding of the combination diet. Abbreviations: SPN, sphingomyelin; PC, phosphatidylcholine; PS/PI, mixture of phosphatidylserine and phosphatidylinositol; PE, phosphatidylethanolamine; CL, cardiolipin. 20:4, 20:4n6; 22:4, 22:4n6; 20:5, 20:5n3; 22:5, 22:5n3; 22:6, 22:6n3.
| Control | Whole Brain | - | 1.31 | 0.53 | 0.75 | 1.18 |
| FUNG | Whole Brain | - | 2.33 | 0.68 | 0.94 | 0.73 |
| FISH | Whole Brain | - | 0.99 | 0.41 | 0.50 | 0.36 |
| FUNG +FISH | Whole Brain | - | 1.20 | 0.50 | 0.67 | 1.08 |
| Control | Hippocampus | - | 2.96 | 0.50 | 0.79 | 1.30 |
| FUNG | Hippocampus | - | 4.18 | 0.67 | 0.96 | 1.09 |
| FISH | Hippocampus | - | 1.86 | 0.44 | 0.51 | 0.76 |
| FUNG +FISH | Hippocampus | - | 2.45 | 0.52 | 0.62 | 0.92 |
| Control | Liver | 0.83 | 2.14 | 8.02 | 2.00 | 0.69 |
| FUNG | Liver | 1.91 | 9.73 | 12.51 | 3.53 | 1.97 |
| FISH | Liver | 0.32 | 0.32 | 1.52 | 0.35 | 0.16 |
| FUNG +FISH | Liver | 0.90 | 1.48 | 2.93 | 0.62 | 0.39 |
Figure 1Graphical representation of the trend and spread of the hepatic microarray data. Blue dots indicate the highest fold change for each probe set on the Affymetrix Mu11K chip, where the highest fold change was identified by examining all fold changes in every possible pairwise comparison between diets. Those probe sets that were identified as absent (by Affymetrix software) across all dietary treatments were treated as unchanged and therefore not considered in the limit fold change (LFC) selection model. The trend within this dataset indicates that as absolute expression increases (along the x-axis), fold changes decrease, i.e. the chance of seeing large fold changes with highly expressed genes is minimal. The 5% LFC line of best fit (red line) takes this observed trend into account and identifies the upper 5% of those probe sets with the greatest fold changes within predefined bins (model parameters fully explained in [27]). The 329 probe sets that lie above the 5% LFC line are those genes defined as differentially regulated. Green circles represent the hepatic genes discussed in the current manuscript and black squares represent those genes validated by real time PCR. When examining the spread of the genes discussed and validated, it is apparent that genes were selected across the entire range of absolute values and not concentrated in one area. Furthermore, as the validation data (which had 86% concordance with microarray data; see [27]) lies across the entire range of absolute expression levels, a high degree of confidence is established for the genes discussed within the present manuscript.
Figure 2Venn diagrams depicting the top 10 GO functional categories in the hippocampus and liver. Examining the top 10 GO classifications for cellular component (CC), biological process (BP), and molecular function (MF) indicated that functional commonalties (overlapping circles) in response to LC-PUFAs exist between the two organs, implying that molecular responses to dietary LC-PUFA occurs via common biological pathways rather than through identical genes. Additional organ-specific functions are also indicated (individual circles).
Differentially expressed genes in response to dietary LC-PUFAs in (A) hippocampus and (B) liver. Table includes gene categories discussed in the manuscript. Genes are grouped by functional category, sorted alphabetically, and annotated with NCBI LocusLink. Average difference intensity (ADI) represents gene absolute expression, and was used to calculate fold changes. Differentially expressed genes were clustered with a combined k-means/hierarchical approach. Asterisk (*) indicates ADIs significantly different from control diet, using 5% LFC gene selection model equations (LFChippocampus = 1.36 + (90/min ADI); LFCliver = 1.52+(100/min ADI)).
| Ar | androgen receptor | Mm.4470 | 83 | 209* | 136 | 101 | H1-K2 |
| Atoh4 | atonal homolog 4 (Drosophila) | Mm.42017 | 21 | 97 | 74 | 119* | H1-K2 |
| Btf3 | basic transcription factor 3 | Mm.1538 | 992 | 522* | 475* | 877 | H5-K5 |
| Dbp | D site albumin promoter binding protein | Mm.3459 | 111 | 206 | 84 | 154 | H1-K2 |
| Ddb1 | damage specific DNA binding protein 1 | Mm.29623 | 239 | 299 | 242 | 139 | H4-K4 |
| Dscr1 | Down syndrome critical region homolog 1 (human) | Mm.56 | 304 | 258 | 138* | 130* | H5-K3 |
| E2f3 | E2F transcription factor 3 | Mm.6333 | 110 | 55 | 214 | 80 | H3-K1 |
| Elk1 | ELK1, member of ETS oncogene family | Mm.3064 | 613 | 425 | 690 | 402 | H3-K1 |
| Hdac1 (Rpd3) | high homology to histone deacetylase 1 | Mm.2602 | 393 | 231 | 411 | 353 | H3-K1 |
| Hoxd12 | homeo box D12 | Mm.57124 | 436 | 368 | 403 | 234* | H4-K4 |
| Idb1 | inhibitor of DNA binding 1 | Mm.444 | 148 | 169 | 344* | 238 | H3-K1 |
| Idb3 | inhibitor of DNA binding 3 | Mm.110 | 41 | 117 | 156* | 138 | H1-K2 |
| Nhlh1 | nescient helix loop helix 1 | Mm.2474 | 111 | 198 | 79 | 132 | H1-K2 |
| Pax9 | paired box gene 9 | Mm.5035 | 104 | 20 | 165 | 77 | H3-K1 |
| Pcbp3 | poly(rC) binding protein 3 | Mm.143816 | 187 | 180 | 52* | 184 | H5-K5 |
| Purb | purine rich element binding protein B | Mm.154651 | 391 | 313 | 172* | 246 | H5-K3 |
| Apod | apolipoprotein D | Mm.2082 | 325 | 423 | 575* | 456 | H3-K1 |
| Htr4 | 5 hydroxytryptamine (serotonin) receptor 4 (5-HT) | Mm.20440 | 20 | 130* | 76 | 89 | H1-K2 |
| Pomc | proopiomelanocortin | Mm.21878 | 51 | 304* | 80 | 71 | H1-K2 |
| Prkcd | protein kinase C, delta (PKC) | Mm.2314 | 461 | 297 | 353 | 263* | H5-K3 |
| Siat8e | sialyltransferase 8 (alpha 2, 8 sialytransferase) E | Mm.5173 | 128 | 207 | 49 | 20* | H5-K4 |
| Ttr | transthyretin | Mm.2108 | 304 | 490 | 157* | 687* | H1-K5 |
| Atf4 | activating transcription factor 4 | Mm.641 | 1122 | 910 | 1045 | 647 | H1-K4 |
| Atf5 | activating transcription factor 5 | Mm.1566 | 870 | 505* | 563* | 281* | H3-K3 |
| Dbp | D site albumin promoter binding protein | Mm.3459 | 169 | 581* | 174 | 747* | H5-K5 |
| Eef1a1 | eukaryotic translation elongation factor 1 alpha 1 | Mm.196614 | 1517 | 845* | 1877 | 1642 | H1-K1 |
| Eif4a1 | eukaryotic translation initiation factor 4A1 | Mm.12858 | 125 | 180 | 68 | 218 | H5-K5 |
| Ercc2 | excision repair cross-complementing rodent repair deficiency, complementation group 2 | Mm.56990 | 148 | 142 | 319* | 298* | H1-K1 |
| Gtf2i | general transcription factor II I | Mm.22593 | 89 | 47 | 150 | 20 | H1-K1 |
| HNF-3g | forkhead box A3 (Foxa3) | Mm.42260 | 411 | 501 | 454 | 207* | H2-K4 |
| Hoxd12 | homeo box D12 | Mm.57124 | 127 | 177 | 85 | 44 | H2-K4 |
| Hzf-pending | hematopoietic zinc finger | Mm.14099 | 235 | 328 | 516* | 173 | H1-K4 |
| Klf13 | Kruppel-like factor 13 | Mm.41170 | 257 | 455 | 381 | 515* | H4-K2 |
| Miz1 | Msx-interacting-zinc finger | Mm.6370 | 283 | 453 | 429 | 146 | H2-K4 |
| Nfyb | nuclear transcription factor-Y beta (NF-Y) | Mm.3259 | 121 | 219 | 73 | 195 | H4-K2 |
| Pbx1 | pre B-cell leukemia transcription factor 1 | Mm.61526 | 1587 | 1039 | 1328 | 933* | H3-K3 |
| Rpo2tc1 | RNA polymerase II transcriptional coactivator | Mm.41746 | 461 | 560 | 368 | 292 | H2-K4 |
| Srebp-1 | ethanol induced 6 (sterol regulatory element binding protein-1); Etohi6 | Mm.30133 | 648 | 610 | 310* | 370* | H3-K3 |
| Tceb1l | transcription elongation factor B (SIII), polypeptide 1 (15 kDa),-like | Mm.42944 | 420 | 549 | 672* | 744* | H5-K5 |
| Tcf2 | transcription factor 2 | Mm.7226 | 151 | 121 | 244 | 20* | H1-K4 |
| Tcf7 | transcription factor 7, T-cell specific | Mm.31630 | 212 | 237 | 203 | 568* | H5-K5 |
| Tcfe3 | EST highly similar to transcription factor E3 | Mm.25762 | 114 | 135 | 203 | 20 | H1-K4 |
| Thrsp; Spot14 | thyroid hormone responsive SPOT14 homolog (Rattus) | Mm.28585 | 2481 | 2947 | 2353 | 1505* | H2-K4 |
| Usf2 | upstream transcription factor 2 | Mm.15781 | 180 | 209 | 32* | 191 | H5-K2 |
| Acas1 | acetyl-Coenzyme A synthetase 1 (AMP forming) | Mm.22719 | 497 | 200* | 297* | 113* | H3-K3 |
| Acly | ATP citrate lyase (ACL) | N/A | 2513 | 939* | 1117* | 530* | H3-K3 |
| Acly | ATP citrate lyase (ACL) | N/A | 3197 | 1568* | 1754* | 878* | H3-K3 |
| Acly | ATP citrate lyase (ACL) | N/A | 456 | 115* | 64* | 51* | H3-K3 |
| Acly | ATP citrate lyase (ACL) | N/A | 603 | 278* | 252* | 163* | H3-K3 |
| Elovl2; Ssc2 | elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 | Mm.2567 | 3010 | 2291 | 1780* | 1690* | H3-K3 |
| Elovl3; Cig30 | elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 | Mm.21806 | 517 | 421 | 983* | 317 | H1-K1 |
| Facl2 | fatty acid Coenzyme A ligase, long chain 2 | Mm.28962 | 514 | 709 | 677 | 926* | H5-K5 |
| Fasn | fatty acid synthase (FAS) | Mm.3760 | 5214 | 2715* | 4104 | 966* | H1-K5 |
| Scd1 | stearoyl-Coenzyme A desaturase 1 | Mm.140785 | 9783 | 8749 | 9493 | 5541* | H1-K4 |
| Acadm | acetyl-Coenzyme A dehydrogenase, medium chain (MCAD) | Mm.10530 | 1364 | 2014 | 1774 | 2261* | H4-K2 |
| Aldh1a1 | aldehyde dehydrogenase family 1, subfamily A1 | Mm.4514 | 2387 | 3917* | 4274* | 4091* | H4-K2 |
| Aldh1a7 | aldehyde dehydrogenase family 1, subfamily A7 | Mm.14609 | 1717 | 1977 | 3208* | 2264 | H1-K1 |
| Cpt1a | carnitine palmitoyltransferase 1, liver | Mm.18522 | 734 | 1285* | 1058 | 1272* | H4-K2 |
| Cpt2 | carnitine palmitoyltransferase 2 | Mm.29499 | 418 | 673 | 791* | 690* | H4-K1 |
| Crat | carnitine acetyltransferase | Mm.20396 | 58 | 82 | 190* | 71 | H1-K1 |
| Ech1 | enoyl coenzyme A hydratase 1 (delta 3,5-delta 2,4-dienoyl-CoA isomerase) | Mm.2112 | 1239 | 1388 | 2031* | 1731 | H1-K1 |
| Camk2b | calcium/calmodulin-dependent protein kinase II, beta | Mm.4857 | 152 | 139 | 20* | 84 | H3-K3 |
| Cam-Pde 1c | calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1c | N/A | 98 | 61 | 75 | 584* | H5-K5 |
| G6pc | glucose-6-phosphatase, catalytic (G6Pase) | Mm.18064 | 1065 | 1224 | 1669* | 553* | H1-K4 |
| Got1 | glutamate oxaloacetate transaminase 1, soluble | Mm.19039 | 976 | 798 | 656 | 467* | H3-K3 |
| Gpam | glycerol-3-phosphate acyltransferase, mitochondrial (GPAT) | Mm.87773 | 1184 | 683* | 989 | 526* | H3-K4 |
| Hspa5 | heat shock 70kD protein 5 (glucose-regulated protein, 78kD) | Mm.918 | 2802 | 1996 | 3014 | 1820* | H1-K4 |
| Pck1 | phosphoenolpyruvate carboxykinase 1, cytosolic (PEPCK) | Mm.42246 | 1376 | 2913* | 2198* | 2369* | H4-K2 |
| Pck1 | phosphoenolpyruvate carboxykinase 1, cytosolic (PEPCK) | Mm.42246 | 964 | 1550 | 1352 | 1652* | H4-K2 |
| Pck1 | phosphoenolpyruvate carboxykinase 1, cytosolic (PEPCK) | Mm.42246 | 243 | 647* | 452* | 633* | H4-K2 |
| Pck1 | phosphoenolpyruvate carboxykinase 1, cytosolic (PEPCK) | Mm.42246 | 320 | 660* | 564* | 744* | H4-K2 |
| Cyp1a2 | cytochrome P450, 1a2, aromatic compound inducible | Mm.15537 | 3952 | 5021 | 2839* | 4187 | H2-K2 |
| Cyp2a4 | cytochrome P450, 2a4 | Mm.14781 | 922 | 2682* | 1100 | 2362* | H4-K2 |
| Cyp2b9 | cytochrome P450, 2b9, phenobarbitol inducible type a | Mm.876 | 57 | 161 | 241* | 146 | H4-K1 |
| Cyp3a11 | cytochrome P450, steroid inducible 3a11 | Mm.21193 | 4777 | 7297 | 8429* | 6542 | H4-K1 |
| Cyp3a16 | cytochrome P450, 3a16 | Mm.30303 | 1438 | 2805* | 2835* | 2282* | H4-K2 |
| Cyp4a10 | cytochrome P450, 4a10 | Mm.10742 | 335 | 894* | 1566* | 1010* | H4-K1 |
| Cyp4a14 | cytochrome P450, 4a14 | Mm.7459 | 20 | 160* | 385* | 51 | H1-K1 |
| Cypf13 | cytochrome P450 CYP4F13 | Mm.22045 | 600 | 834 | 529 | 439 | H2-K2 |
| Por | P450 (cytochrome) oxidoreductase | Mm.3863 | 54 | 208* | 119 | 232* | H4-K2 |
| Abca1 | ATP-binding cassette, sub-family A (ABC1) member 1 | Mm.369 | 550 | 121* | 217* | 270* | H3-K3 |
| Abca7 | ATP-binding cassette, sub-family A (ABC1) member 7 | Mm.103351 | 20 | 20 | 20 | 144* | H5-K5 |
| Abce1 | ATP-binding cassette, sub-family E (OABP)member 1 | Mm.5831 | 118 | 116 | 310* | 124 | H1-K1 |
| Cd36 | CD36 antigen | Mm.18628 | 247 | 223 | 591* | 170 | H1-K1 |
| Fabp5 | fatty acid binding protein 5, epidermal (E-FABP) | Mm.741 | 3236 | 593* | 384* | 238* | H3-K3 |
| Slc10a1 | solute carrier family 10 (sodium/bile acid cotransporter family), member 1 (Ntcp) | Mm.104295 | 845 | 877 | 534* | 1005 | H5-K5 |
| Fpps | farnesyl pyrophosphate synthase | Mm.39472 | 794 | 327* | 510* | 421* | H3-K3 |
| Hmgcs2 | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2, mitochondrial (HMG-CoA2) | Mm.10633 | 3592 | 4491 | 4590 | 5822* | H5-K5 |
| Apoa4 | apolipoprotein A-IV | Mm.4533 | 2011 | 781* | 629* | 117* | H3-K3 |
| Apoa4 | apolipoprotein A-IV precursor | Mm.4533 | 194 | 60* | 46* | 20* | H3-K3 |
| ApoB-100 | EST highly similar to apolipoprotein B-100 precursor | Mm.29123 | 2675 | 5710* | 5005* | 5395* | H4-K2 |
| Apoc1 | apolipoprotein CI | Mm.182440 | 5719 | 3465* | 6337 | 5953 | H1-K1 |
| Apoc2 | apolipoprotein CII | Mm.28394 | 3199 | 2511 | 2143* | 2005* | H3-K3 |
| Apoe | apolipoprotein E | Mm.138866 | 6425 | 6438 | 9632* | 5253 | H1-K1 |
Ratios of FA with n+2 carbons/FA with n carbons in the diet and various hepatic PL pools. There was some evidence to indicate elongase activity may have been impaired in some cases, as explained in the text. n, refers to the number of carbons in the FA chain length; Eth, Ether; refer to previous Tables for other abbreviations. Groups sharing a superscript in common are not statistically significant, ANOVA, P < 0.05.
| Control | 12.60 | 0.29 | 0.06 | 1.57 | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | - | 0.00 | 0.00 | 0.29 |
| FUNG | 13.57 | 0.33 | 0.08 | 0.96 | 4.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | - | 1.63 | - | - | 0.01 | 0.00 | 0.33 |
| FISH | 8.95 | 0.29 | 0.09 | 0.91 | 1.14 | 0.00 | 0.01 | 0.44 | 1.75 | 0.01 | - | 0.43 | - | - | 0.05 | 0.37 | 0.29 |
| FUNG+FISH | 9.61 | 0.32 | 0.10 | 0.71 | 4.00 | 0.00 | 0.01 | 0.36 | 2.38 | 0.02 | - | 1.22 | - | - | 0.01 | 0.29 | 0.32 |
| Control | - | 0.26a | 0.43b | 5.99a | 0.47b | 1.02c | - | - | - | - | - | 0.23a | - | - | 0.00a | 0.40a | - |
| FUNG | - | 0.33b | 0.40b | 7.89b | 0.49b | 0.54ab | - | - | - | - | - | 0.15a | - | - | 0.18b | 0.39a | - |
| FISH | - | 0.37b | 0.23a | 7.49ab | 0.37a | 0.91bc | - | - | - | - | - | 0.45b | - | - | 0.00a | 0.99b | - |
| FUNG+FISH | - | 0.34b | 0.38b | 9.72c | 0.43ab | 0.36a | - | - | - | - | - | 0.25a | - | - | 0.00a | 0.32a | - |
| Control | 141.61a | 0.34b | 0.02a | 0.17b | - | 2.29d | 0.02b | 0.08a | - | 0.02b | - | 10.79b | - | 0.51c | 0.02b | 0.61b | - |
| FUNG | 162.36b | 0.35b | 0.01a | 0.22b | - | 1.82c | 0.02b | 0.11ab | - | 0.01a | - | 4.81a | - | 0.04a | 0.02b | 1.98c | - |
| FISH | 191.31c | 0.26a | 0.02a | 0.14a | - | 1.24b | 0.02b | 0.14b | - | 0.02b | - | 19.56c | - | 0.73d | 0.01a | 0.12a | - |
| FUNG+FISH | 216.95d | 0.26a | 0.02a | 0.10a | - | 0.98ab | 0.01a | 0.23c | - | 0.01a | - | 7.66ab | - | 0.17ab | 0.01a | 0.69b | - |
| Control | 10.65a | 5.57c | 0.01a | 0.29b | 0.58b | - | 0.07b | 0.35a | 0.99ab | 0.08c | 0.86c | 5.68a | - | - | 0.02b | 0.40a | - |
| FUNG | 32.30b | 4.96bc | 0.01a | 0.31b | 0.41ab | - | 0.06a | 0.50ab | 1.14b | 0.05ab | 0.39b | 4.73a | - | - | 0.02b | 2.41b | - |
| FISH | 17.66a | 4.41ab | 0.02b | 0.15a | 0.31a | - | 0.06a | 0.36a | 0.56a | 0.05ab | 0.37ab | 14.63b | - | - | 0.02b | 0.58a | - |
| FUNG+FISH | 42.49b | 3.83a | 0.02b | 0.16a | 0.35a | - | 0.07b | 0.84b | 0.57a | 0.03a | 0.23ab | 6.18a | - | - | 0.01a | 1.61ab | - |
| Control | 82.93a | 0.80a | 0.01a | 0.18c | - | 3.02c | 0.05b | 0.16a | - | 0.02a | 0.00a | 4.70b | 0.12a | 0.047a | 0.02b | 43.94c | 0.38d |
| FUNG | 120.36b | 0.92c | 0.01a | 0.13bc | - | 2.19b | 0.04a | 0.15a | - | 0.03b | 0.00a | 3.10a | 0.00a | 0.174a | 0.04c | 121.04d | 0.59c |
| FISH | 141.69b | 0.71b | 0.02b | 0.10ab | - | 1.49a | 0.05a | 0.18a | - | 0.02a | 0.29b | 6.78c | 0.11a | 0.793b | 0.01a | 3.98a | 0.33b |
| FUNG+FISH | 137.18b | 0.78ab | 0.02b | 0.08a | - | 1.23a | 0.05a | 0.32b | - | 0.03b | 0.10a | 3.06a | 0.35b | 0.134a | 0.02b | 22.62b | 0.53ab |
| Control | 4.14a | 0.84ab | 0.08b | 0.32a | - | 1.44b | 0.05b | 0.14a | 1.87c | 0.01a | 0.00a | 5.80a | 0.00a | - | 0.09b | - | - |
| FUNG | 4.58b | 0.66b | 0.06a | 0.72b | - | 1.06a | 0.04a | 0.51b | 0.59a | 0.01a | 0.03b | 15.91b | 0.22b | - | 0.09b | - | - |
| FISH | 5.69bc | 1.09a | 0.08b | 0.21a | - | 1.45b | 0.05b | 0.11a | 1.15ab | 0.01a | 0.00a | 7.20ab | 0.26b | - | 0.05a | - | - |
| FUNG+FISH | 6.70c | 1.02a | 0.09c | 0.33a | - | 1.39b | 0.05b | 0.50b | 0.66a | 0.01a | 0.01ab | 15.38b | 0.42c | - | 0.05a | - | - |
Ratios of FA in hepatic PL pools with a Δ9 double bond/equivalent FA without a Δ9 double bond. There was some evidence to indicate Δ9 desaturase activity may have been impaired, as explained in the text. Abbreviations: FA, fatty acid; PL, phospholipid; see Table 1 for additional abbreviations. Δ9 desaturase is also known as stearoyl-Coenzyme A desaturase (Scd1). Groups sharing a superscript in common are not statistically significant, ANOVA, P < 0.05.
| Control | 0.03b | 0.18b | 0.05c | 1.27b | 0.04c | 0.09b | 0.04c | 0.49c | 0.50b |
| FUNG | 0.01a | 0.08a | 0.03b | 0.81a | 0.03b | 0.09b | 0.04c | 0.37b | 0.30a |
| FISH | 0.01a | 0.25b | 0.03b | 1.28b | 0.02b | 0.10b | 0.03b | 0.37b | 0.49b |
| FUNG+ FISH | 0.01a | 0.09a | 0.02a | 0.80a | 0.02b | 0.06a | 0.02a | 0.24a | 0.23a |
Dietary composition of the experimental diets. Values represent the weight percent of each component in the diet, wet weight basis. Fungal oil was the source of AA; fish oil was the source of DHA. Suppliers are confidential. Fungal and fish oils were replaced with MCT (medium chain triacylgylcerols) to provide the same total fat content of each diet.
| Powdered Diet AIN 93, fat free | 90.0 | 90.0 | 90.0 | 90.0 |
| Milk fat | 0.4 | 0.4 | 0.4 | 0.4 |
| MCT oil | 5.1 | 4.0 | 3.1 | 2.1 |
| Palm olein | 1.2 | 1.2 | 1.2 | 1.2 |
| Trisun oil | 1.9 | 1.9 | 1.9 | 1.9 |
| Soy oil | 1.5 | 1.5 | 1.5 | 1.5 |
| Fungal oil rich in AA | 0.0 | 1.1 | 0.0 | 1.1 |
| Fish oil rich in DHA | 0.0 | 0.0 | 1.9 | 1.9 |
Fatty acid composition of the experimental diets. The sources of all oils are given in Table 5. Values represent g FA/100 g total FA, following 3 determinations. The FUNG diet contained ca. 5% AA; the FISH diet contained ca. 5% DHA; and the FUNG+FISH diet contained ca. 5% of AA and 5% of DHA.
| 4:0 + 6:0 | 0.2 | 0.4 | 0.1 | 0.3 |
| 8:0 | 27.2 | 21.3 | 16.9 | 11.1 |
| 10:0 | 22.9 | 18.0 | 14.3 | 9.4 |
| 12:0+13:0+14:0+ 14:1n5+15:0+17:0 | 1.6 | 1.6 | 2.7 | 2.7 |
| 16:0 | 7.9 | 9.2 | 11.9 | 13.2 |
| 18:0 | 2.3 | 3.0 | 3.5 | 4.2 |
| 18:1n9 | 24.8 | 25.4 | 27.0 | 27.6 |
| 18:1n9 | 0.3 | 0.3 | 0.8 | 0.8 |
| 18:2n6 | 11.4 | 12.3 | 11.9 | 12.8 |
| 18:3n6 | - | 0.3 | 0.1 | 0.4 |
| 18:3n3 | 1.0 | 1.0 | 1.1 | 1.1 |
| 18:4n3 | - | - | 0.1 | 0.1 |
| 20:0 | 0.1 | 0.2 | 0.3 | 0.4 |
| 20:1n9 | 0.1 | 0.1 | 0.2 | 0.2 |
| 20:2n6 | - | 0.1 | 0.1 | 0.2 |
| 20:3n6 | - | 0.4 | 0.1 | 0.5 |
| 20:4n6 | - | 4.7 | 0.4 | 5.1 |
| 20:5n3 | - | 0.3 | 1.1 | 1.4 |
| 22:0+22:1n9+24:0+24:1n9+26:0+unknown | 0.3 | 1.3 | 1.9 | 2.9 |
| 22:4n6 | - | 0.1 | 0.0 | 0.1 |
| 22:5n3 | - | - | 0.4 | 0.4 |
| 22:6n3 | - | - | 5.2 | 5.2 |